Frontier Capital Management Co. LLC Purchases New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Frontier Capital Management Co. LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 151,010 shares of the company's stock, valued at approximately $9,415,000. Frontier Capital Management Co. LLC owned approximately 0.45% of TransMedics Group at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Clear Creek Financial Management LLC bought a new stake in TransMedics Group in the fourth quarter worth $352,000. Vaughan Nelson Investment Management L.P. boosted its holdings in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in TransMedics Group in the fourth quarter worth $6,734,000. Finally, Peregrine Capital Management LLC boosted its holdings in TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after purchasing an additional 25,814 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

TransMedics Group stock traded up $7.23 during trading hours on Monday, hitting $118.73. 2,071,635 shares of the stock were exchanged, compared to its average volume of 1,350,968. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $4.02 billion, a P/E ratio of 126.31 and a beta of 1.91. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The business's 50-day moving average is $79.56 and its two-hundred day moving average is $75.05.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating and issued a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a report on Friday. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Oppenheimer upped their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.